Correlating the behavior of polymers in solution as precipitation inhibitor to its amorphous stabilization ability in solid dispersions

被引:98
作者
Chauhan, Harsh [1 ]
Hui-Gu, Chong [2 ]
Atef, Eman [3 ]
机构
[1] Creighton Univ, Sch Pharm & Hlth Profess, Omaha, NE 68164 USA
[2] Agios Pharmaceut, Cambridge, MA 02139 USA
[3] MCPHS Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA
关键词
crystallization; interaction; polymers; precipitation; solid dispersion; WATER-SOLUBLE DRUGS; ORAL ABSORPTION; WEAK BASES; SPECTROSCOPIC CHARACTERIZATION; DOSAGE FORMS; DISSOLUTION; SOLUBILITY; STATE; INDOMETHACIN; DIPYRIDAMOLE;
D O I
10.1002/jps.23539
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Our major goals were to understand the mechanism of dipyridamole (DPD) precipitation inhibition in the presence of polymers and to correlate the polymers-mediated precipitation inhibition in solution to the amorphous stabilization in the solid state. A continuous UV spectrophotometer was used to monitor the DPD concentration with time in the absence and presence of different polymers. Six polymers: PVP K90, hydroxypropylmethylcellulose (HPMC), Eudragit E100, Eudragit S100, Eudragit L100, and PEG 8000 were screened at different drug-to-monomer ratios. Solid dispersions were characterized by X-ray powder diffraction and modulated differential scanning calorimetry, whereas infrared (IR) and Raman were used to investigate the possible drugpolymer interactions. Eudragit E100 and HPMC were found to delay both DPD precipitation initiation time and precipitation rates. Eudragit S100 delayed only the precipitation initiation time and PVP K90 decreased only the precipitation rates. In solid state, Eudragit S100, PVP K90, HPMC, and Eudragit L100 were effective stabilizers of the DPD solid dispersion. Eudragit S100 was found to be most effective DPD-stabilizing polymer. The IR and Raman spectra of the solid dispersion of Eudragit S100 and HPMC showed peak shift, indicating drugpolymer molecular interactions. It is concluded that the drugpolymer interaction plays a significant role in precipitation inhibition and amorphous stabilization. (c) 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:19241935, 2013
引用
收藏
页码:1924 / 1935
页数:12
相关论文
共 36 条
[1]   Crystal modification of dipyridamole using different solvents and crystallization conditions [J].
Adhiyaman, R. ;
Basu, Sanat Kumar .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 321 (1-2) :27-34
[2]   Understanding the Behavior of Amorphous Pharmaceutical Systems during Dissolution [J].
Alonzo, David E. ;
Zhang, Geoff G. Z. ;
Zhou, Deliang ;
Gao, Yi ;
Taylor, Lynne S. .
PHARMACEUTICAL RESEARCH, 2010, 27 (04) :608-618
[3]   Advancing in-vitro drug precipitation testing: new process monitoring tools and a kinetic nucleation and growth model [J].
Arnold, Yvonne E. ;
Imanidis, Georgios ;
Kuentz, Martin T. .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (03) :333-341
[4]   Solubility-excipient classification gradient maps [J].
Avdeef, Alex ;
Bendels, Stefanie ;
Tsinman, Oksana ;
Tsinman, Konstantin ;
Kansy, Manfred .
PHARMACEUTICAL RESEARCH, 2007, 24 (03) :530-545
[5]   Thermoanalytical and spectroscopic characterization of solid state dipyridamole [J].
Berbenni, V ;
Marini, A ;
Bruni, G ;
Maggioni, A ;
Cogliati, P .
JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2002, 68 (02) :413-422
[6]   INTERACTION BETWEEN DIPYRIDAMOLE AND EUDRAGIT-S [J].
BETEN, DB ;
GELBCKE, M ;
DIALLO, B ;
MOES, AJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 88 (1-3) :31-37
[7]   Solid dispersions, Part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs [J].
Bikiaris, Dimitrios N. .
EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (11) :1501-1519
[8]   Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability? [J].
Brouwers, Joachim ;
Brewster, Marcus E. ;
Augustijns, Patrick .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (08) :2549-2572
[9]   Preparation and characterization of solid dispersions of dipyridarmole with a carrier "copolywidonum Plasdone®S-630" [J].
Chen, Shengjun ;
Zhu, Jiabi ;
Ma, Fengqin ;
Fang, Qun ;
Li, Yinghuan .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2007, 33 (08) :888-899
[10]   The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems [J].
Craig, DQM ;
Royall, PG ;
Kett, VL ;
Hopton, ML .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1999, 179 (02) :179-207